Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Effects of NMDA Receptor Antagonism on Cognitive Processes in Healthy Volunteers and Its Reversal by a Dopamine Antagonist: Comparison to Patients With Schizophrenia


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01140620

Organisation Name: University of Manchester

Overal Status: Completed

Start Date: June 2010

Last Update: November 9, 2016

Lead Sponsor: University of Manchester

Brief Summary: The primary objective of this study is:

• To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the dopamine receptor antagonist, risperidone.

The secondary objectives of this study are:

To establish whether patients with schizophrenia are able to reliably complete the biomarker test battery and to assess whether their responses are similar to healthy volunteers treated with ketamine.
To establish a multi-site recruitment and assessment capacity based on shared Standard Operating Procedures across three study centres.

Conditions:
  • Healthy Volunteers
  • Schizophrenia


Total execution time in seconds: 0.20880603790283